-

Prothena to Participate in Stifel 2023 Virtual CNS Days

DUBLIN, Ireland--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Stifel 2023 Virtual CNS Days on Tuesday March 28, 2023 at 10:30 AM ET.

A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Contacts

Investor and Media Contacts:

Investors
IR@prothena.com

Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com

Prothena Corporation plc

NASDAQ:PRTA

Release Summary
Prothena announced today that members of its senior management team will participate in a fireside chat at Stifel 2023 Virtual CNS Days on March 28 .
Release Versions
$Cashtags
Hashtags

Contacts

Investor and Media Contacts:

Investors
IR@prothena.com

Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com

Social Media Profiles
More News From Prothena Corporation plc

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

DUBLIN--(BUSINESS WIRE)--Prothena today reported financial results for the first quarter of 2025 and provided business highlights....

Prothena to Report First Quarter 2025 Financial Results on May 8

DUBLIN--(BUSINESS WIRE)--Prothena today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025....

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

DUBLIN--(BUSINESS WIRE)--Prothena reported financial results for the 4th quarter and full year 2024. The Company also provided business highlights and 2025 financial guidance....
Back to Newsroom